Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Moderna shares soar on positive RSV vaccine trial results
11:41am, Wednesday, 18'th Jan 2023
Moderna Inc stock had added almost 6% on Wednesday morning after the biotechnology company reported positive results from a Phase 3 clinical study involving its vaccine targeting respiratory syncytial
What's happening to Moderna shares on Wednesday?
11:32am, Wednesday, 18'th Jan 2023
Shares of Moderna Inc (NASDAQ: MRNA) gained as much as 8.0% on Wednesday after the biotech giant reported promising results for its respiratory syncytial virus vaccine in older adults.
RSV Vaccine Trial Data Sends Moderna Stock Surging
10:50am, Wednesday, 18'th Jan 2023
Moderna Inc (NASDAQ:MRNA) stock is enjoying vaccine tailwinds today, though outside the realm of Covid this time.
Moderna (MRNA) Stock Pops on RSV Vaccine Trial Results
09:25am, Wednesday, 18'th Jan 2023
Moderna (NASDAQ: MRNA ) stock is on the move Wednesday alongside positive results from its latest mRNA-1345 vaccine trial. That trial covers the use of mRNA-1345 as a vaccine for the respiratory syncy
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
09:12am, Wednesday, 18'th Jan 2023
The Nasdaq looked poised for modest gains once again on Wednesday.
Moderna, Tesla, Charles Schwab, and More Market Movers
05:31am, Wednesday, 18'th Jan 2023
Stocks paused Wednesday as investors reacted to a monetary policy decision from the Bank of Japan and looked ahead to a wave of economic data.
Davos 2023: Moderna CEO says he wants to have mRNA factory on every continent
03:40am, Wednesday, 18'th Jan 2023
Moderna chief executive Stephane Bancel said he would like to have factories making vaccines based on its messenger RNA technology on every continent as the U.S. company prepares to build four facilit
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up
05:03pm, Tuesday, 17'th Jan 2023
Moderna stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84% effective in older adults. The post Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle
Moderna's phase three RSV trial found to be 83.7% effective in older adults
04:55pm, Tuesday, 17'th Jan 2023
CNBC's Meg Tirrell joins 'Closing Bell' to discuss Moderna's phase three trial results for its RSV vaccine, the decision to submit the vaccine for regulatory review and the competitive landscape for R
Moderna stock rallies 5% after respiratory virus vaccine trial meets endpoints
04:26pm, Tuesday, 17'th Jan 2023
Moderna Inc. MRNA, -0.68% shares rallied in the extended session Tuesday after the biotech drug company said results from a late-stage clinical trial for its respiratory virus vaccine met endpoints, a
Moderna says RSV vaccine is 84% effective at preventing disease in older adults
04:05pm, Tuesday, 17'th Jan 2023
RSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC.
Moderna: Wait For The Turn
12:49pm, Monday, 16'th Jan 2023
Moderna, Inc. packed more punches against its critics as it delivered surprisingly positive results on its personalized cancer vaccine study with Merck's Keytruda. However, BioNTech's more ambitious a
3 Biopharma Stocks That Could Help Make You a Fortune
08:30am, Monday, 16'th Jan 2023
All three are protected by sales of in-demand products, with more on the way.
Moderna's Platform Is Game Changing
05:16am, Sunday, 15'th Jan 2023
Moderna has a strong platform of assets that have the potential to revolutionize the treatment of numerous fields. The COVID-19 business will likely continue to generate billions in annualized revenue
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
10:32am, Friday, 13'th Jan 2023
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
